Latest News on Aurobindo Pharma
Unlocking the Emerging Opportunities in India’s Pharmaceutical Industry
The Indian pharmaceutical sector has demonstrated robust growth over the past year, driven by a new trade agreement with the European Union that reduces tariffs on key drug exports. This agreement is expected to enhance India’s position as a global supplier of generic medicines, leading to increased trade volume and job creation. The sector has shown positive momentum in the short term, reflecting a steady rise in investor confidence. Analysts project substantial upside potential for various companies operating in this space.
Several top companies in the sector have been identified as having strong upside potential. Cohance Lifesciences Limited, a technology-driven contract development and manufacturing organization, has a target price of Rs. 1400.00, indicating an upside potential of 33%. Piramal Pharma Limited, a global pharmaceutical company, has a target price of Rs. 271.00, reflecting an upside potential of 32%. Natco Pharma Limited, a vertically integrated pharmaceutical company, has a target price of Rs. 1090.00, indicating an upside potential of 28%.
Other companies with strong upside potential include Aurobindo Pharma Limited, which has a target price of Rs. 1470.00, reflecting an upside potential of 23%, and Blue Jet Healthcare Limited, which has a target price of Rs. 943.00, indicating an upside potential of 19%. Zydus Lifesciences Limited, a global life sciences company, has a target price of Rs. 1040.00, reflecting an upside potential of 18%.
Overall, the outlook for the Indian pharmaceutical sector remains positive, driven by the new trade agreement with the European Union and the growth potential of various companies operating in the space. Analysts recommend a strong buy for Cohance Lifesciences and Piramal Pharma, a buy for Aurobindo Pharma and Blue Jet Healthcare, and a hold for Natco Pharma and Zydus Lifesciences.
The financial performance of these companies has been strong, with many reporting significant year-on-year sales growth. However, some companies have seen a decline in profit after tax (PAT) due to various factors. Despite this, the long-term implications of the trade agreement and the growth potential of the sector are expected to drive growth and innovation in the Indian pharmaceutical industry.
Aurobindo and MSN set to lose US patent protection for Nuplazid in August 2038
A recent US district court ruling has brought relief to Acadia Pharmaceuticals, the manufacturer of Nuplazid, a medication used to treat hallucinations and delusions associated with Parkinson’s disease psychosis. The court’s decision has upheld the validity of a key formulation patent for Nuplazid, which is set to expire in August 2038. This ruling means that generic versions of the medication, including one developed by Aurobindo, will not be able to enter the market until the patent expires.
The court found that Aurobindo’s abbreviated new drug application (ANDA) for a generic version of Nuplazid infringed on Acadia’s patent. Furthermore, the court also ruled that MSN, another company, had already admitted to infringing on the patent. This decision is a significant victory for Acadia, as it protects the company’s exclusive rights to market Nuplazid in the US for several more years.
The ruling is also a blow to generic drug manufacturers, who had been seeking to enter the market with their own versions of Nuplazid. Aurobindo and other companies had been trying to capitalize on the growing demand for treatments for Parkinson’s disease psychosis, which is a significant and underserved market. However, with the court’s decision, these companies will now have to wait until the patent expires in 2038 before they can launch their own generic versions.
The decision is also a testament to the strength of Acadia’s patent portfolio and the company’s ability to defend its intellectual property. Acadia has invested heavily in developing Nuplazid, and the medication has become a key driver of the company’s growth. The court’s ruling ensures that Acadia will be able to continue to reap the benefits of its investment in Nuplazid for several more years.
Overall, the court’s decision is a significant development in the pharmaceutical industry, and it highlights the importance of intellectual property protection in the development of new medications. With the patent for Nuplazid set to expire in 2038, Acadia will have a significant amount of time to continue to market and sell the medication before generic competition enters the market. This will provide the company with a stable source of revenue and allow it to continue to invest in the development of new treatments for Parkinson’s disease and other conditions.
Aurobindo Pharma subsidiary introduces leadership development initiative at Indian Management and Technology Institute Hyderabad
Aurobindo Pharma, a leading generic drug manufacturer, has launched a six-month post-graduation certification in leadership (CLP) program at the Institute of Management Technology, Hyderabad (IMT Hyderabad). The program, introduced through Aurobindo’s wholly-owned subsidiary Apitoria, aims to transform promising professionals into dynamic leaders by equipping them with essential skills in managing themselves, teams, business, and change.
The CLP program consists of 13 days of classroom sessions, spread across six modules, which will be delivered through a blend of traditional and modern teaching methods. The program is designed to be immersive and practice-oriented, providing participants with hands-on experience and real-world applications. The curriculum is tailored to help middle managers develop the skills and confidence needed to take on larger responsibilities and drive business growth.
According to U.N.B. Raju, Senior Vice President of Corporate HR at Aurobindo Pharma, the introduction of the CLP program is a testament to the company’s commitment to nurturing talent and enabling the growth of middle management. “It is an important step in grooming our middle managers to take on larger responsibilities with confidence and agility,” Raju said. The program is expected to play a critical role in connecting strategy with execution, driving business success, and fostering a culture of leadership and innovation within the organization.
The launch of the CLP program is a strategic investment in the development of Aurobindo Pharma’s human capital, recognizing the critical role that middle managers play in driving business growth and success. By partnering with IMT Hyderabad, Aurobindo Pharma aims to provide its employees with access to world-class education and training, empowering them to excel in their roles and contribute to the company’s continued success. With the CLP program, Aurobindo Pharma is poised to develop a pipeline of talented leaders who can drive business growth, innovation, and excellence in the pharmaceutical industry.
The Indian market for active pharmaceutical ingredients has experienced significant revenue generation.
The India Active Pharmaceutical Ingredients (API) market is expected to experience significant growth, with an estimated value of USD 14.81 billion in 2025 and a projected value of USD 25.23 billion by 2032, at a compound annual growth rate (CAGR) of 7.9%. This growth is driven by increasing demand for pharmaceuticals, innovation, and the presence of key players in the market.
The report provides a comprehensive analysis of the India Active Pharmaceutical Ingredients market, including market size, revenue, production, and CAGR. It also highlights the competitive landscape, with key players such as Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Cipla, and Sun Pharmaceutical Industries. The report provides a detailed review of major players, covering their financials, product benchmarking, and competitive strategies.
The market is segmented by manufacturer, synthesis type, drug type, application, product type, and formulation. The report also analyzes the geographical landscape of the market, with a focus on North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
The report identifies key drivers and trends in the market, including technological advancements, regulatory and policy shifts, and emerging industry trends. It also highlights the opportunities and challenges in the market, including supply chain issues and evolving consumer behavior.
The report provides actionable insights and quantitative analysis of market segments, trends, estimations, and dynamics. It also includes Porter’s Five Forces analysis for strategic decision-making and segmentation analysis to identify market opportunities.
The key benefits of the report include:
* Quantitative analysis of market segments, trends, estimations, and dynamics
* Insights into key drivers, restraints, and opportunities
* Porter’s Five Forces analysis for strategic decision-making
* Segmentation analysis to identify market opportunities
* Revenue mapping of major countries by region
* Benchmarking and positioning of market players
* Analysis of regional and global trends, key players, and growth strategies
The report is a valuable resource for industry leaders, investors, and decision-makers, providing a comprehensive and detailed analysis of the India Active Pharmaceutical Ingredients market. It is available for purchase, with a 25% discount for a limited time.
Aurobindo Pharma subsidiary receives US FDA approval for generic version of Bristol Myers Squibb’s cancer treatment
Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Dasatinib Tablets in various strengths. The approved product is bioequivalent and therapeutically equivalent to Bristol-Myers Squibb Company’s (BMS) Sprycel Tablets. Dasatinib Tablets are used to treat certain types of leukemia, including Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia.
The approval is significant, as the estimated market size for the product is $1.8 billion for the twelve months ending February 2025, according to IQVIA MAT numbers. The company plans to launch the product by June. This is the 181st Abbreviated New Drug Application (ANDA) approval received by Eugia Pharma Specialities Group (EPSG) facilities, which manufacture both oncology oral and sterile specialty products.
Dasatinib Tablets are indicated for the treatment of newly diagnosed adults with Ph+ chronic myeloid leukemia in chronic phase, as well as adults with chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy. The product is also used to treat adults with Ph+ acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
The approval demonstrates Aurobindo Pharma’s commitment to expanding its product portfolio and increasing its presence in the global pharmaceutical market. The company’s subsidiary, Eugia Pharma Specialities, has a strong track record of receiving FDA approvals, with 181 ANDA approvals to date. The launch of Dasatinib Tablets is expected to contribute to the company’s revenue growth and help it achieve its business objectives.
Overall, the FDA approval of Dasatinib Tablets is a significant milestone for Aurobindo Pharma and its subsidiary, Eugia Pharma Specialities. The product has the potential to make a significant impact in the treatment of certain types of leukemia, and the company is well-positioned to capitalize on the growing demand for affordable and effective pharmaceuticals.
Stock Market Updates for Aurobindo Pharma
Recent Updates
Aurobindo Pharma secures FDA nod for generic version of Xarelto.
Aurobindo Pharma, a leading Indian pharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for the generic equivalent of Xarelto (Rivaroxaban), a popular anticoagulant drug. The generic version, Rivaroxaban Tablets, will be used to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have undergone knee or hip replacement surgery.
Xarelto is a blockbuster drug developed by Johnson & Johnson and is marketed by Bayer. According to Aurobindo Pharma, it is one of the most widely used oral anticoagulant drugs, with over 1.5 million prescriptions filled in the US alone in 2020. However, it is notoriously difficult to manufacture and has been the subject of several patent disputes.
Aurobindo Pharma’s generic version of Xarelto is the first to receive FDA approval and will be available in the US market in the coming weeks. The company claims that its generic version is identical in composition, strength, and dosage form to the branded version, and is therefore substitutable.
The approval is significant for Aurobindo Pharma, which has been aggressively pursuing FDA approvals for generic versions of blockbuster drugs. The company has over 200 ANDA (Abbreviated New Drug Application) filings pending with the FDA, including several for complex products such as Xarelto.
The pricing of Aurobindo Pharma’s generic Xarelto will likely be significantly lower than the branded version, which could potentially disrupt the market dynamics. The branded Xarelto is currently priced at around $120 per 20-mg tablet, while Aurobindo Pharma’s generic version will be priced much lower, around $4-5 per tablet.
The generic approval is also seen as a shot in the arm for India’s pharmaceutical industry, which has been under pressure due to rising competition from China and patent-related issues. Aurobindo Pharma’s success will likely encourage other Indian companies to invest in developing generic versions of complex products, which could help to reduce the country’s dependence on branded drugs.
In conclusion, Aurobindo Pharma’s FDA approval for the generic equivalent of Xarelto is a significant development in the pharmaceutical industry, particularly for the Indian company and the country’s pharma sector as a whole. The generic version is expected to be priced lower than the branded version, which could disrupt the market dynamics and provide patients with a more affordable option.
Aurobindo Pharma receives US FDA approval for Rivaroxaban Tablets
Aurobindo Pharma, a generic drugmaker, has received final approval from the US FDA to manufacture and market Rivaroxaban Tablets USP in the strength of 2.5 mg. This approval is based on the company’s demonstration of bioequivalence and therapeutic equivalence to the reference listed drug Xarelto 2.5 mg of Janssen Pharmaceuticals Inc. The company plans to launch the product by June, following the approval.
Rivaroxaban Tablet USP is used to treat various conditions, including nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism, and for the prophylaxis of blood clots in patients undergoing knee or hip replacement surgery. The approved product has an estimated US market size of $447 million for the 12 months ending February 2025.
Aurobindo Pharma has also received tentative approval from the US FDA for Rivaroxaban Tablets USP in strengths of 10 mg, 15 mg, and 20 mg. The estimated US market size for all strengths of Rivaroxaban tab USP is $8.5 billion for the 12 months ending February 2025.
Aurobindo Pharma arm CuraTeQ Biologics completes successful Phase 1 pharmacokinetic study of investigational bone drug.
Aurobindo Pharma’s subsidiary, CuraTeQ Biologics, has successfully completed a Phase 1 pharmacokinetics study for its investigational bone drug. The study aimed to evaluate the drug’s ability to maintain a stable level in the bloodstream over a prolonged period.
The Phase 1 study was a randomized, open-label, single-dose escalation design, involving 24 healthy male subjects. Participants received a single dose of the investigational bone drug, and pharmacokinetic (PK) parameters were measured to assess the drug’s absorption, distribution, metabolism, and elimination (ADME) profile.
The study results showed that the investigational bone drug was well-tolerated, with no serious adverse events reported. The study also demonstrated that the drug follows a predictable PK profile, with a rapid absorption and elimination, and a relatively small variability in exposure across participants.
The successful completion of this study is a significant milestone for CuraTeQ Biologics, as it sets the stage for further clinical development of the investigational bone drug. The company plans to continue evaluating the safety and efficacy of the drug in larger, more detailed studies, with the goal of submitting a new drug application to regulatory authorities in the future.
The investigational bone drug, a humanized monoclonal antibody, is being developed as a potential treatment for osteoporosis and related bone disorders. It is designed to selectively target a specific protein responsible for bone dissolution, thereby reducing bone loss and improving bone density.
Overall, the successful completion of this Phase 1 study is an important step forward in the development of this innovative treatment for bone disorders. CuraTeQ Biologics’ work has the potential to bring a new and effective therapy to patients with osteoporosis and related conditions, and the company is committed to advancing this research through further clinical trials and regulatory submissions.
US Announces Plans to Impose Tariffs on Pharma Imports: Impact on India’s $8.7 Billion Market
The US government, under President Donald Trump, has announced plans to impose new tariffs on pharmaceutical imports, which could significantly impact India, the top supplier of generic drugs to the US. The move aims to push pharmaceutical manufacturing back to the US, but analysts warn that it could have far-reaching consequences for both countries. India’s pharmaceutical sector, which generates a significant portion of its revenue from the US market, could face major setbacks. Indian companies such as Dr Reddy’s, Aurobindo Pharma, Sun Pharma, Zydus Lifesciences, and Gland Pharma, which rely on the US market for a substantial part of their revenue, may be particularly affected.
The tariffs, expected to be “major,” could lead to increased costs for US consumers and insurers, and potentially cause inflation and drug shortages. The US heavily relies on low-cost Indian generics to maintain affordability in healthcare, and a tariff regime could disrupt this arrangement. Indian drugmakers already operate on tight margins, and tariffs would force them to raise prices, making their products less competitive in the US market.
As the US government continues to develop its trade policy, Indian pharma exports may face an uncertain future, further adding pressure to the industry grappling with FDA compliance challenges. The US-India trade relationship is already under strain, and the tariff move could exacerbate tensions between the two nations. Analysts warn that both countries will bear the brunt of this move, which could set back India’s competitiveness in the global pharmaceutical market.
Citi cites low risk of US tariffs on Indian pharma, favoring Torrent Pharma and Divi’s.
Citibank has analyzed the potential impact of US tariffs on Indian pharmaceutical companies and has assigned a low probability to such an event. The brokerage firm simulated a 10% tariff scenario and found that companies with a high exposure to US generics, such as Zydus, Dr. Reddy’s Laboratories, and Aurobindo Pharma, could face a 9-12% reduction in earnings before interest, taxes, depreciation, and amortization (EBITDA). However, if part of the tariffs is passed on to buyers, the impact could be reduced to 5-6%.
On the other hand, companies with lower exposure to US generics, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories, would be less affected, with an estimated 1-3% hit to EBITDA. Citi’s preferred picks in the Indian pharmaceutical sector, these companies have diversified portfolios and are less reliant on the US generics market.
The report also notes that if tariffs are imposed, they may not be fully passed on to US buyers due to various factors, including competition, industry fragmentation, and the influence of buying consortiums focused on lowering prices. Citi believes that the probability of tariffs on Indian generics is low, citing the limited manufacturing of generics in the US, the high dependence on Indian generics, and the risk of drug shortages if Indian suppliers exit the market.
The brokerage firm concludes that while the imposition of tariffs is a low-probability event, the potential impact on Indian pharmaceutical companies varies significantly based on their exposure to the US generics market. Overall, the report suggests that investors should focus on companies with diversified portfolios and lower reliance on the US generics market, such as Torrent Pharma, Sun Pharma, and Divi’s Laboratories.
Aurobindo Pharma Terminates Vaccine License Agreement with Hilleman Labs
Aurobindo Pharma, a pharmaceutical company, has terminated its licensing agreement with Hilleman Laboratories Singapore Pte Ltd for the development, manufacturing, and commercialization of a pediatric pentavalent vaccine candidate. The agreement was signed in September 2023 and was set to expire in 2025. As Auro Vaccines, the subsidiary responsible for the vaccine development, is not a material part of the company, Aurobindo Pharma expects the termination to have no significant impact on its financials or subsidiaries.
The agreement required Auro Vaccines to make milestone payments to Hilleman Laboratories upon achieving specific development and clinical study outcomes, as well as pay royalties to the Singapore-based company once the vaccine candidate was commercialized. Despite the termination, Aurobindo Pharma is not expected to experience any significant impact, and the company will make any necessary disclosures if the situation changes in the future.
The termination is viewed as a “non-material event” by Aurobindo Pharma, which suggests that the company does not expect to incur any substantial financial losses or liabilities as a result. This decision may indicate that the company is re-evaluating its priorities and focusing on more promising opportunities. As the deal was still in its early stages, the termination may not have significant implications for the pharmaceutical industry or the development of pediatric vaccines.
Unleashing New Frontiers: Aurobindo Pharma’s Diversification Drive Paves the Way for Future Growth
Aurobindo Pharma, a leading drugmaker, is focusing on sustaining profitability and turnover in the face of rising global uncertainties. According to Chief Financial Officer Santhanam Subramanian, the company’s strategy is centered on scale and diversity, with a goal of expanding into new verticals such as injectables, peptides, and biosimilars. This diversification will help minimize the impact of a potential tariff hike in the US and maintain margins.
Aurobindo has been steadily expanding its presence in the market, starting with a small API business in India, followed by the US, Europe, and other parts of the world. The company is also entering the Chinese market, which is expected to contribute to its growth in 2-3 years.
The company’s diversified portfolio allows it to overcome the risks associated with price erosion, as 10% of its top products account for 20% of its US turnover. Aurobindo does not differentiate between “bread and butter” and high-growth segments, nurturing all verticals independently to ensure consistent contribution to overall growth.
In terms of cash flow generation, Aurobindo is planning to expand its existing projects and open new plants, including a US-based plant and a biosimilar facility. The company’s strong cash flow generation allows it to strategically allocate capital towards new verticals and expansion projects.
Aurobindo’s net debt stands at $84 million, with projections to generate $200-300 million annually. The company has a robust product pipeline, with over 850 ANDAs filed and 150-200 awaiting approval. The new verticals of biosimilars, Eutect, Terany, and Biologics are expected to drive growth in the coming years.
Overall, Aurobindo Pharma is confident in its ability to sustain healthy margins and drive growth through its focus on scale and diversity, robust cash flow generation, and strong product pipeline.